SERPINA1 and alpha 1-antitrypsin deficiency: These studies may provide potential clinical significance because AAT-based, autophagy-related, adjunctive therapy could be beneficial for treatment of NTM-PD patients who have underlying diseases such as bronchiectasis along with AAT deficiency.